IGM Biosciences Inc
IGMS1.390USD
-0.070-4.79%
Cierre 04/23, 16:00（ET）Cotizaciones retrasadas 15 min
82.91MCap. mercado
PérdidaP/E TTM
Información de IGM Biosciences Inc Compañía
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Información de la empresa
Código de la empresaIGMS
Nombre de la empresaIGM Biosciences Inc
Fecha de salida a bolsaSep 18, 2019
Fundada en2012
Director ejecutivoDr. Mary Beth Harler, M.D.
Número de empleados149
Tipo de títulosOrdinary Share
Fin del año fiscalSep 18
Dirección325 E Middlefield Rd
CiudadMOUNTAIN VIEW
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94043-4003
Teléfono16509657873
Sitio Webhttps://igmbio.com/
Código de la empresaIGMS
Fecha de salida a bolsaSep 18, 2019
Fundada en2012
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
339.70K
-2.11%
Mr. Misbah Tahir, CPA
Mr. Misbah Tahir, CPA
Chief Financial Officer
Chief Financial Officer
180.32K
-3.91%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Independent Director
Independent Director
125.00K
--
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
90.88K
+0.92%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
62.75K
+2.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lisa L. Decker, Ph.D.
Dr. Lisa L. Decker, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Dr. Mary Beth Harler, M.D.
Dr. Mary Beth Harler, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
339.70K
-2.11%
Mr. Misbah Tahir, CPA
Mr. Misbah Tahir, CPA
Chief Financial Officer
Chief Financial Officer
180.32K
-3.91%
Dr. William Strohl, Ph.D.
Dr. William Strohl, Ph.D.
Independent Director
Independent Director
125.00K
--
Mr. Jakob Haldor Topsoe
Mr. Jakob Haldor Topsoe
Independent Director
Independent Director
90.88K
+0.92%
Ms. Christina Teng Topsoe
Ms. Christina Teng Topsoe
Independent Director
Independent Director
62.75K
+2.09%
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
No datos encontrados
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.68M
0.00%
Por negocio
Por región
No datos encontrados
Accionista
Hora de actualización: mié., 2 de abr
Hora de actualización: mié., 2 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Baker Bros. Advisors LP
11.91%
T. Rowe Price Associates, Inc.
10.18%
Invus Public Equities Advisors, LLC
9.68%
Redmile Group, LLC
8.58%
Sanofi
4.18%
Other
55.45%
Estadísticas de accionistas
Accionista
Proporción
Baker Bros. Advisors LP
11.91%
T. Rowe Price Associates, Inc.
10.18%
Invus Public Equities Advisors, LLC
9.68%
Redmile Group, LLC
8.58%
Sanofi
4.18%
Other
55.45%
Tipo
Accionista
Proporción
Investment Advisor
27.23%
Investment Advisor/Hedge Fund
15.31%
Hedge Fund
13.66%
Individual Investor
5.49%
Corporation
4.18%
Research Firm
3.12%
Bank and Trust
0.04%
Pension Fund
0.02%
Other
30.94%
Participación institucional
Hora de actualización: lun., 3 de mar
Hora de actualización: lun., 3 de mar
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
247
34.19M
99.42%
-4.51M
2024Q4
261
34.20M
100.37%
-4.65M
2024Q3
262
33.88M
99.73%
-5.05M
2024Q2
269
34.16M
101.16%
-4.19M
2024Q1
277
34.60M
103.20%
-3.37M
2023Q4
277
33.51M
100.77%
-4.17M
2023Q3
286
34.23M
103.22%
-3.29M
2023Q2
291
34.31M
107.60%
+1.63M
2023Q1
295
29.58M
100.36%
-4.78M
2022Q4
307
29.75M
104.43%
-3.74M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
4.10M
11.91%
+1.91K
+0.05%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.50M
10.18%
-369.20K
-9.54%
Dec 31, 2024
Invus Public Equities Advisors, LLC
3.33M
9.68%
--
--
Dec 31, 2024
Redmile Group, LLC
2.95M
8.58%
-120.35K
-3.92%
Dec 31, 2024
Sanofi
1.44M
4.18%
+1.44M
--
Dec 31, 2024
Goldman Sachs & Company, Inc.
965.88K
2.81%
-279.57K
-22.45%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
952.96K
2.77%
+138.07K
+16.94%
Dec 31, 2024
The Vanguard Group, Inc.
896.35K
2.61%
+6.15K
+0.69%
Dec 31, 2024
Fidelity Management & Research Company LLC
473.43K
1.38%
-346.10K
-42.23%
Dec 31, 2024
State Street Global Advisors (US)
459.45K
1.34%
-10.34K
-2.20%
Dec 31, 2024
Ver más
ETF relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Range Cancer Immunotherapy ETF
0.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.15%
Invesco NASDAQ Future Gen 200 ETF
0.07%
Global X Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Ver más
Range Cancer Immunotherapy ETF
Proporción0.15%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.15%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.07%
Global X Russell 2000 ETF
Proporción0%
Fidelity MSCI Health Care Index ETF
Proporción0%
iShares Russell 3000 ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
No datos encontrados
División de acciones
Fecha
Tipo
Relación
No datos encontrados
Fecha
Tipo
Relación
No datos encontrados